However, the liver is also involved in hematopoiesis during embryologic development, in innate immunity, and in digestion through the production of bile.
Yet we understand little about how liver function is altered during critical illness, and how these alterations are best measured. Hyperbilirubinemia, the classic marker of hepatic dysfunction, provides little insight into what is happening within the liver. Th e prevalence of hyperbilirubinemia appears to be on the decline, perhaps because of declining use of total parenteral nutrition and of transfusion, although it is an independent risk factor for increased mortality [7, 8] . Moreover, the presence and prognostic import of hyperbilirubinemia appear to derive more from the fact that this marker delineates a population of patients with irreversible end-stage liver disease rather than a transient and potentially reversible process that might be considered a component of the Multiple Organ Dysfunction Syndrome. Greater insight into other aspects of hepatic dysfunction that might be both deranged in critical illness and measured in critically ill patients is clearly needed.
Th e Jena group is making substantial strides in addressing this need, and is bringing attention to striking abnormalities in hepatic biotransformation and excretion that arise in severely ill patients [9] . Th ey have shown previously that hepatocellular transport at the canalicular pole of the hepatocyte is impaired in sepsis, with the result that a spectrum of hepatotoxic materials accumulates within the septic liver. Th ey now extend these important observations [1] .
Gonnert and colleagues use a combination of elegant imaging techniques to detect clearance of two dyes that are metabolized by the liver -indocyanine green and DY635 -in a lethal rat model of intra-abdominal infection resulting from intraperitoneal administration of feces. Th ey show that dye is cleared from the circulation and taken up readily by liver cells, but that its appearance in bile is delayed, indicating that defective cellular function primarily involves excretion of transformed molecules from the hepatocyte into the biliary canaliculi, rather than its delivery to, or uptake by, liver cells. Impaired excretion of dye is further evidenced as Abstract Liver dysfunction is believed to contribute to the metabolic derangements of critical illness. The cellular basis of liver dysfunction is poorly understood and its consequences largely unknown. Recent work by Gonnert and colleagues sheds additional light. Using two imaging techniques to track the clearance of biotransformed dyes by the liver in a rat model of intra-abdominal infection, the authors show that the predominant defect in sepsis lies in the excretion of biotransformed molecules from the hepatocyte into the bile canaliculi. Their work both points to a new aspect of hepatic dysfunction through focus on a role in the metabolic derangements of sepsis and suggests a possible strategy to diagnose and monitor this process in critically ill patients.
sus tained persistence of dye within the liver, and its reduced appearance within the lumen of the gastrointestinal tract.
Th is body of work and the ongoing evolution of the authors' investigations hold exciting and important possibilities. First, the work provides valuable insight into the nature of hepatocellular dysfunction in critical illness, shifting the focus from microcirculatory impairments or abnormalities in uptake of hepatically transformed compounds to their excretion into the biliary tree and gastrointestinal tract. Th e signifi cance of accumulation of a spectrum of compounds -toxins, drugs, bilirubin, and other metabolic substances -within the hepatocyte is uncertain, and is fertile ground for future study. Does their accumulation subsequently result in impaired uptake from the liver microvasculature? If so, then toxins or drugs may accumulate in the circulation, their normal metabolism impeded by failure of their excretion from the hepatocyte. If this is the case, then those alterations may be modifi able by altering drug doses or by extracorporeal removal, and eventually by pharma co logic interventions that correct the excretory derange ment. Does impaired hepatocellular excretion aff ect the normal synthetic function of the hepatocyte, and therefore impair its ability to synthesize proteins such as acute phase reactants or coagulation factors? Does impaired excretion alter the ability of the liver to take up glucose and store it as glycogen, and therefore may hepatocellular dysfunction emerge as a component of the syndrome of insulin resistance that is so commonly seen in sepsis? Do alterations in hepatocyte function result in altered Kupff er cell function, and therefore contribute to the immunologic alterations of sepsis?
Moreover, as techniques of near-infrared fl uorescence imaging improve, the technologies described by Gonnert and colleagues may well fi nd a clinical role as a noninvasive test of hepatic dysfunction in the critically ill patient, and so provide a measure of liver function that is more sensitive, sophisticated, and relevant than the serum bilirubin level.
Despite its fundamental and varied role in normal homeostasis, to the intensivist the liver remains a frustratingly opaque black box whose inner workings are obscure. Studies like those of Gonnert and colleagues are begin ning to lift the lid, if only a little, and to shine a light on a largely unexplored area in the support of the critically ill patient.
